{"id":28394,"date":"2025-07-23T08:52:47","date_gmt":"2025-07-23T08:52:47","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/samsung-biologics-reports-second-quarter-2025-financial-results\/"},"modified":"2025-07-23T08:52:47","modified_gmt":"2025-07-23T08:52:47","slug":"samsung-biologics-reports-second-quarter-2025-financial-results-2","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=28394","title":{"rendered":"Samsung Biologics reports second quarter 2025 financial results"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2395686\/Samsung_Biologics_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Recorded Q2&#8217;25 consolidated revenue of <span class=\"xn-money\">KRW 1,289.9 billion<\/span><\/li>\n<li>Recorded Q2&#8217;25 consolidated operating profit of <span class=\"xn-money\">KRW 475.6 billion<\/span><\/li>\n<li>Solid momentum sustained through capacity ramp-up and stable project execution<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">INCHEON, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>&#8220;Our second quarter results demonstrate continued strong momentum across our business,&#8221; said <span class=\"xn-person\">John Rim<\/span>, CEO and President of Samsung Biologics. &#8220;With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value\u2014setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence.&#8221;<\/p>\n<p><b>SECOND QUARTER 2025 RESULTS<\/b><\/p>\n<p>Samsung Biologics posted consolidated revenue of <span class=\"xn-money\">KRW 1,289.9 billion<\/span> and operating profit of <span class=\"xn-money\">KRW 475.6 billion<\/span> in the second quarter of 2025. On a standalone basis, the company reported revenue of <span class=\"xn-money\">KRW 1,014.2 billion<\/span> and operating profit of <span class=\"xn-money\">KRW 477.0 billion<\/span>. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4.<\/p>\n<p>In the first half of 2025, standalone revenue surpassed <span class=\"xn-money\">KRW 2 trillion<\/span>, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached <span class=\"xn-money\">USD 2.4 billion<\/span>, bringing up the cumulative value to <span class=\"xn-money\">USD 18.7 billion<\/span>.<\/p>\n<div align=\"center\">\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"4\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[Consolidated Earnings, KRW billion]\u00a0\u00a0\u00a0<\/span><\/p>\n<p><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prnsbtb1 prnrbrb1 prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q2&#8217;25<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q2&#8217;24<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">YoY Change<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Revenue<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,289.9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,156.9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">133.0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Operating Profit<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">475.6<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">434.5<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">41.1<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EBITDA<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">653.8<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">582.6<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">71.2<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>BUSINESS UPDATES<\/b><\/p>\n<p>In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients&#8217; manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards.<\/p>\n<p>The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making.<\/p>\n<p>In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry&#8217;s greater demands to ultimately maximize corporate value and sustainable growth potential.<\/p>\n<p>On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility.<\/p>\n<p><b>About Samsung Biologics<\/b><\/p>\n<p>Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.<\/p>\n<p>With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.<\/p>\n<p>Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and <span class=\"xn-location\">Japan<\/span>. Samsung Biologics America supports clients based in the U.S. and <span class=\"xn-location\">Europe<\/span>, while its <span class=\"xn-location\">Tokyo<\/span> sales office serves the APAC region.<\/p>\n<p>Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/samsungbiologics.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/samsungbiologics.com\/<\/a>.<\/p>\n<p><b>Samsung Biologics Media Contact<\/b><\/p>\n<p><span class=\"xn-person\">Claire Kim<\/span>, Head of Marketing &amp; Global Communications<br \/><a href=\"mailto:cair.kim@samsung.com\" target=\"_blank\" rel=\"nofollow\">cair.kim@samsung.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2395686\/Samsung_Biologics_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Recorded Q2&#8217;25 consolidated revenue of <span class=\"xn-money\">KRW 1,289.9 billion<\/span><\/li>\n<li>Recorded Q2&#8217;25 consolidated operating profit of <span class=\"xn-money\">KRW 475.6 billion<\/span><\/li>\n<li>Solid momentum sustained through capacity ramp-up and stable project execution<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">INCHEON, <span class=\"xn-location\">South Korea<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">July 23, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>&#8220;Our second quarter results demonstrate continued strong momentum across our business,&#8221; said <span class=\"xn-person\">John Rim<\/span>, CEO and President of Samsung Biologics. &#8220;With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value\u2014setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence.&#8221;<\/p>\n<p><b>SECOND QUARTER 2025 RESULTS<\/b><\/p>\n<p>Samsung Biologics posted consolidated revenue of <span class=\"xn-money\">KRW 1,289.9 billion<\/span> and operating profit of <span class=\"xn-money\">KRW 475.6 billion<\/span> in the second quarter of 2025. On a standalone basis, the company reported revenue of <span class=\"xn-money\">KRW 1,014.2 billion<\/span> and operating profit of <span class=\"xn-money\">KRW 477.0 billion<\/span>. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4.<\/p>\n<p>In the first half of 2025, standalone revenue surpassed <span class=\"xn-money\">KRW 2 trillion<\/span>, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached <span class=\"xn-money\">USD 2.4 billion<\/span>, bringing up the cumulative value to <span class=\"xn-money\">USD 18.7 billion<\/span>.<\/p>\n<div align=\"center\">\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"4\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">[Consolidated Earnings, KRW billion]\u00a0\u00a0\u00a0<\/span><\/p>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prnsbtb1 prnrbrb1 prnbbbs prnsblb1\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q2&#8217;25<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Q2&#8217;24<\/span><\/p>\n<\/td>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">YoY Change<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Revenue<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,289.9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">1,156.9<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">133.0<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Operating Profit<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">475.6<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">434.5<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">41.1<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">EBITDA<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">653.8<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">582.6<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">71.2<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><b>BUSINESS UPDATES<\/b><\/p>\n<p>In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients&#8217; manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards.<\/p>\n<p>The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making.<\/p>\n<p>In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry&#8217;s greater demands to ultimately maximize corporate value and sustainable growth potential.<\/p>\n<p>On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility.<\/p>\n<p><b>About Samsung Biologics<\/b><\/p>\n<p>Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.<\/p>\n<p>With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.<\/p>\n<p>Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and <span class=\"xn-location\">Japan<\/span>. Samsung Biologics America supports clients based in the U.S. and <span class=\"xn-location\">Europe<\/span>, while its <span class=\"xn-location\">Tokyo<\/span> sales office serves the APAC region.<\/p>\n<p>Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/samsungbiologics.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/samsungbiologics.com\/<\/a>.<\/p>\n<p><b>Samsung Biologics Media Contact<\/b><\/p>\n<p><span class=\"xn-person\">Claire Kim<\/span>, Head of Marketing &amp; Global Communications<br \/><a href=\"mailto:cair.kim@samsung.com\" target=\"_blank\" rel=\"nofollow\">cair.kim@samsung.com<\/a>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-28394","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/28394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28394"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/28394\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28394"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28394"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}